Medshine Discovery Inc.

Shandong Danhong Pharmaceutical Co., Ltd.

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Heilongjiang Zhenbaodao Pharmaceutical Co, Ltd

Novartis Ag

Fujian Akeylink Biotechnology Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd.

Phaeno Therapeutics Co., Ltd.

Shangdong Danhong Pharmaceutical Co., Ltd.

Zhigan Jiang

Haiying He

Shuhui Chen

Jian Li

Weihua Shi

Jing Wang

Xiaoping Zheng

Jianhua Xia

Kunmin Lai

Zheng Wang

Hongwei Li

Feng Xu

Weidong Li

Linghui Wu

Minggao Zeng

Lixia Han

Xiao Xun Zhang

Zhen Gong

Jikui Sun

Yaxun Yang

Zhiliang Yuan

Chen Zhang

Xing Liu

Yan Wang

Xiaolin Li

Jie Li

Javier De Vicente Fidalgo

Cheng Hu

Xiaoxin Chen

Chaofeng Long

Zhiqiang Liu

Hui Zhou

Peichao Lu

Xiaojing Michael Wang

Daniel Mutnick

Alexey A Rivkin

Juan Yu

Fei Hong

Tingting Yin

Zhiliang Chen

Folkert Reck

Jinming Huang

Jinxia Lin

Wosenu Mergo

Yongjin Xu

Yichao Zhuang

Zhiyi Luo

Shicong Wang

Lihong Lan

Peng Shao

Xiao Zhang

Leilei Gao

Jiwen Xu

Weixiang Zhou

Kaili Jian

Colin Keith Skepper

Zhixiang Pan

Guoping Hu

An aminopyridine compound, which is specifically a compound represented by formula (P), and a pharmaceutically acceptable salt thereof. The compound can be used to prepare drugs for treating deep fungal infections.

Aminopyridine compound and application thereof

Disclosed by the present invention are a crystal form A of a compound represented by formula (I), a compound represented by formula (II) and a crystal form B thereof, as well as an application of the crystal form A of the compound represented by formula (I), the compound represented by formula (II) and the crystal form B thereof in the preparation of a drug for the treatment diseases associated with the herpes simplex virus.

Crystal forms of thiazole compound and application thereof

Disclosed are crystal form A and crystal form B of a compound represented by formula (I), and application thereof in the preparation of medicaments for treating HBV-related diseases.

Crystal form of tri-cycle compound and application thereof

Disclosed are a thieno[2,3-c]pyridazin-4(1H)-one derivative as an ACC1 or ACC2 inhibitor and an application thereof in preparing a drug as an ACC1 or ACC2 inhibitor. In particular, disclosed is a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof. 

Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof

Disclosed are a crystal form of a thieno[2,3-c]pyridazine-4(1H)-one compound, a preparation method therefor and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2. 

Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof

Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2. 

Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof

The present invention relates to an amorphous pyrrolidine derivative as a PPAR agonist and a preparation method thereof.

Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof

The present invention provides a salt and crystal form of a modified andrographolide compound and a preparation method and pharmaceutical use thereof. 

Salt and crystal form of modified andrographolide compound and preparation method thereof

Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases. 

Tri-cycle compound and applications thereof

Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof. 

Process for preparing 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[D]imidazol-2-yl)methyl)spiro[azetidine-3,3&#x2032;-indolin]-2&#x2032;-one

The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof. 

Modified compound of andrographolide

Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses. 

Thiazole derivative and applications thereof

Crystal form B of 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)methyl)spiro[azetidine-3,3&#x2032;-indolin]-2&#x2032;-one

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. 

Pyrrolidine derivatives as PPAR agonists

Crystal form A of 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo [d]imidazol-2-yl)methyl)spiro[azetidine-3,3&#x2032;-indolin]-2&#x2032;-one

Growing community of inventors

Shanghai, China

Zhigan Jiang